Dublin, December 22, 2020 (GLOBE NEWSWIRE) – Added to the report “Global Market Report of Monoclonal Breast Cancer Antibodies 2020-30: Growth and Conversion of COVID-19” ResearchAndMarkets.com’s offering.
Global Market Report Monoclonal Breast Cancer Antibodies (mAbs) 2020-30: The Growth and Conversion of COVID-19 provides its strategists, marketers and senior executives with the essential information they need to assess the market for global breast cancer monoclonal antibodies (mabs).
The global breast cancer monoclonal antibodies market is expected to decrease from $ 13.57 billion in 2019 to $ 12.60 billion in 2020 at a complex annual growth rate (CAGR) of -7.10%. The decline is largely due to the COVID-19 revolution that has led to limited containment measures including social distance, remote working, and the closure of businesses and other commercial activities leading to operational challenges. The entire supply chain was disrupted, adversely affecting the market. The market is then expected to recover and reach $ 16.45 billion in 2023 at a CAGR of 9.29%.
Key players in the breast cancer monoclonal antibodies (mAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma.
The breast cancer monoclonal antibodies (mAbs) market includes the sale of monoclonal antibodies by organizations (organizations, single vendors and partners) that produce breast cancer monoclonal antibodies used as a treatment for cancer breast either as monotherapy or combination therapy. Revenue includes sales of nude mAbs and condensed mAbs. The companies involved in the breast cancer monoclonal antibodies market are mainly focused on the research, development, and production of monoclonal antibodies used in early and advanced breast cancer, in-situ ductal carcinoma, tri- breast cancer negative, inflammatory breast cancer, and others.
In March 2019, AstraZeneca, a UK-based global biopharmaceutical company that locates, develops and trades prescription drugs in the fields of medicine such as oncology, cardiovascular, kidney & metabolism and respiratory, entered into for a partnership with Daiichi Sankyo Company, Limited with an advance payment of $ 1.35 billion. The collaboration agreement is on the global development and commercialization of trastuzumab deruxtecan (DS-8201), which is a potential new antibody-drug (ADC) drug combination and targeted cancer treatment. Except in Japan (exclusive rights for Daiichi Sankyo), the companies develop and trade deruxtecan trastuzumab. Daiichi Sankyo Company Limited is a global pharmaceutical company based in Japan that creates innovative new and generic medicines and new methods of drug detection and delivery.
Alternative treatments and natural remedies are becoming increasingly popular worldwide and this is expected to impact the revenue of breast cancer monoclonal antibodies manufacturing companies. Remedies in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are becoming popular and slowly replacing some traditional hospital practices. For example, ayurvedic medicine, an ancient Indian medicine system uses a range of techniques and remedies for cancer. Many herbs used in Ayurveda have anti-cancer properties.
Also, the global homeopathic product market is expected to reach $ 18.6 billion by the end of 2027. In 2018, the National Cancer Institute identified promising vaccine results in HER2-positive cancers including breast, ovarian, lung, colorectal cancers, and gastroesophageal, where they used patient immune cells to treat their HER2-positive cancers by genetically modifying them to customize a personalized vaccine. These factors are expected to continue during the expected period and limit the demand for breast cancer monoclonal antibodies market.
Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has become more effective and less toxic than the traditional treatment options. Targeted cancer drugs are drugs or substances that inhibit cancer growth by inhibiting molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these treatments is to eliminate cancerous cells in the body while leaving normal cells unharmed.
By focusing on changes in the cell that are specific to cancer, this treatment may be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a method of treatment in which a patient receives two or more drugs (or other therapeutic agents) for a single disease.
An increase in breast cancer is expected to drive the growth of the breast cancer monoclonal antibodies market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the US. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the United States.
This includes women currently receiving treatment and women who have completed treatment. According to the World Health Organization (WHO), 627,000 people died of breast cancer in 2018, which is about 15% of women’s cancer deaths. Therefore, an increase in breast cancer is expected to lead to a global increase in the breast cancer monoclonal antibodies market.
Key topics covered:
1. Management Summary
2. Features of breast cancer monoclonal market (mAbs)
3. Monoclonal Breast Cancer Antibodies (mAbs) Market Size and Growth
3.1. Historical Market of Monoclonal Cancer Breast Antibodies (mAbs), 2015 – 2019, $ Billion
3.1.1. Market drivers
3.1.2. Market constraints
3.2. Global Antibodies Market Antibodies Global Breast Cancer (mAbs), 2019 – 2023F, 2025F, 2030F, $ Billion
3.2.1. Market drivers
3.2.2. Market constraints
4. Monoclonal Breast Cancer Antibodies (mAbs) Market Classification
4.1. Global Breast Cancer Monoclonal Antibodies Market (mAbs), segmented by product, historical and forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Mabs Naked
- Mixed Mabs
4.2. Global Breast Cancer Monoclonal Antibodies Market (mAbs), end-user segmentation, historical and forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Ospadalan
- Retail Pharmacy
5. Regional and Rural Market Analysis of Breast Cancer Monoclonal Antibodies (mAbs)
5.1. Global Breast Cancer Monoclonal Antibodies Market (mAbs), broken down by region, historical and forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Breast Cancer Monoclonal Antibodies Market (mAbs), broken down by country, historical and forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Companies mentioned
- Amgen
- Mylan
- Merck
- Novartis
- GlaxoSmithKline
- Daiichi Sankyo
- Biocad
- Boehringer Ingelheim
- Squibb Bristol-Myers
- BioPharma Array
- Therapeutic Celldex
- Celltrion
- Roche
- Immunomedics
- MacroGenics
- Pfizer
- Solar pharmaceutical industries
- Teva Medications
- Puma Biotechnology
- Seattle Genetics
- AstraZeneca
- Eddingpharm
- Eisai
- Biopharma Galena
- ImmunoGen
For more information about this report, visit https://www.researchandmarkets.com/r/da7jn6
Research and Markets also offers Custom Search services providing targeted, complete and unique search.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900